Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PKBO

Peak Bio (PKBO) Stock Price, News & Analysis

Peak Bio logo

About Peak Bio Stock (NASDAQ:PKBO)

Advanced Chart

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.11
52-Week Range
$0.00
$0.26
Volume
66,140 shs
Average Volume
8,940 shs
Market Capitalization
$520.31 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.

Receive PKBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Peak Bio and its competitors with MarketBeat's FREE daily newsletter.

PKBO Stock News Headlines

Trump’s true trade war strategy
The media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada the 51st state because he’s desperate for critical minerals… They think his involvement in Ukraine is just another resource grab… They think his tariffs will wreck the economy… But they’re all missing the bigger picture.
Peak Bio Inc (PKBO)
Peak Bio, Inc. (PKBO)
What Peak 65 Means for My Gen X Clients
AKARI THER.ADR/2000 -,01 (CLA.MU)
See More Headlines

PKBO Stock Analysis - Frequently Asked Questions

Peak Bio, Inc. (NASDAQ:PKBO) released its quarterly earnings data on Tuesday, November, 12th. The company reported $0.06 EPS for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that Peak Bio investors own include Check-Cap (CHEK), Pulmonx (LUNG), Minerva Neurosciences (NERV), GlycoMimetics (CBIO), Adicet Bio (ACET), Absci (ABSI) and Aeglea BioTherapeutics (AGLE).

Company Calendar

Last Earnings
11/12/2024
Today
6/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PKBO
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.83 million
Pretax Margin
-4,433.33%

Debt

Sales & Book Value

Annual Sales
$370 thousand
Price / Cash Flow
N/A
Book Value
($0.90) per share
Price / Book
-0.03

Miscellaneous

Free Float
18,523,000
Market Cap
$520.31 thousand
Optionable
Not Optionable
Beta
1.75
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:PKBO) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners